Standalone Audited Financial Result for the Quarter and Year ended on 31.03.2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Achyut Healthcare reported revenue of Rs 1,159.47 Lakhs for FY26, up 280% from Rs 304.75 Lakhs in FY25, driven by significant business growth. However, net profit declined 38.7% to Rs 31.57 Lakhs from Rs 51.47 Lakhs despite higher sales, indicating cost pressures. EBITDA margin compressed sharply from 19.3% to 4.7%, with total expenses rising disproportionately to revenue. The company migrated from SME to Main Board of BSE in January 2026 and adopted Ind AS accounting standards for the first time, requiring restatement of prior year figures. Operating cash flow turned positive at Rs 113.45 Lakhs compared to negative Rs 399.83 Lakhs in FY25. A preferential issue of 58 lakh equity shares was allotted on March 23, 2026.
Strong revenue growth is offset by profit decline and margin compression, suggesting the company is investing heavily in growth or facing cost pressures. The positive operating cash flow and Ind AS adoption are positive developments. Shareholders should monitor if profitability normalises in coming quarters.